db-1305
mAbexperimentalADC
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 19, 2022 (NCT05438329)
Timeline
Indications
Studied for
Mechanism of action
TACSTD2 inhibitor
Chemistry & pharmacology
- Payload
- unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06953089 | Phase 2 | Jul 18, 2025 | Biontech, DualityBio Inc. |
| NCT05438329 | Phase 1/Phase 2 (Phase 2) | Jul 19, 2022 | DualityBio Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| DualityBio Inc. | For profit | 2 | 2 | 1 | 2022 |
| Biontech | For profit | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1